Illuminating discussion on the #ethics of control group treatment in #RCTs. Scroll down to find many possible examples in #nephrology - like a textbook
IRBs to keep eyes open
Cristian Pattaro
Simulpub number 6 at #ERA26
Obi beats tacrolimus in membranous nephropathy
www.nejm.org/doi/full/10.... in NEJM
No surprise after MENTOR
www.nejm.org
Studies of obinutuzumab, a type II anti-CD20 antibody, have shown efficacy in the treatment of hematologic cancers and autoimmune diseases. An evaluation of the efficacy and safety of obinutuzumab ...